XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2
STATEMENTS OF CASH FLOWS - USD ($)
3 Months Ended
May 31, 2022
May 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (231,737) $ (316,283)
Adjustments to reconcile net loss to net cash used by operating activities:    
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D. 151,334 215,926
Changes in operating assets and liabilities    
Prepaids 579 (521)
Accounts payable 13,925 (2,071)
Accrued liabilities 26,766 18,514
NET CASH USED BY OPERATING ACTIVITIES (39,133) (84,435)
CASH FLOWS FROM FINANCING ACTIVITIES    
Contribution of capital 40,517 84,967
NET CASH PROVIDED BY FINANCING ACTIVITIES 40,517 84,967
NET INCREASE IN CASH 1,384 532
CASH AT BEGINNING OF PERIOD 3,382 62
CASH AT END OF PERIOD $ 4,766 $ 594